Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

COG Addresses Unmet Needs in Pediatric NHL

May 25th 2018

Birte Wistinghausen, MD, shares her insight on the potential for targeted therapies in the treatment of pediatric non-Hodgkin lymphoma, and the steps that the Children’s Oncology Group is taking to cure all patients with this disease.

Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG

May 24th 2018

A number of biological factors, including age at diagnosis, symptom duration at diagnosis, and HIST1H3B mutation status, are associated with survival ≥2 years in children and young adults with diffuse intrinsic pontine glioma, a brainstem malignancy with a median survival

Autoimmune Disease May Have Complicated Treatment for Pediatric ITP

May 23rd 2018

An underlying autoimmune condition may have played a role in making a 13-year-old patient refractory to treatment for immune thrombocytopenia.

Ponatinib Shows Promise in Pediatric/Adolescent ALL Patients

May 23rd 2018

Ponatinib (Iclusig) induced a complete remission in one pediatric/adolescent patient with Philadelphia chromosome-positive acute lymphoblastic leukemia, and demonstrated promising clinical activity in another.

Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy

May 22nd 2018

Tocilizumab resolved cytokine release syndrome in patients with relapsed/refractory pediatric B-cell acute lymphoblastic leukemia without reducing the efficacy of tisagenlecleucel.

Dr. Baker on the Importance of Symptom Management in Children With Cancer

May 22nd 2018

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses the importance of symptom management in children with cancer.

Larotrectinib Inches Closer to FDA Approval for TRK+ Cancers

May 21st 2018

Anna Farago, MD, PhD, discusses the biology of larotrectinib, as well as the importance of genetic testing for molecular alterations like TRK in patients with locally advanced solid tumors.

Dr. Geller on Renal Rhabdoid Tumors in Pediatric Patients

May 17th 2018

James I. Geller, MD, medical director, Kidney and Liver Tumors Program, Cincinnati Children’s Hospital Medical Center, discusses renal rhabdoid tumors in pediatric patients.

Nelarabine Boosts 4-Year DFS Above 90% in Pediatric/AYA T-Cell Cancers

May 17th 2018

Adding nelarabine to escalating-dose methotrexate induced a 4-year disease-free survival rate of 91% in a cohort of pediatric and young adult patients with newly diagnosed T-cell cancers.

Dr. Patterson Discusses Concerns With TKIs in Children With CML

May 15th 2018

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses concerns regarding the use of tyrosine kinase inhibitors in the treatment of children with chronic myeloid leukemia.

Expert Explains State of TKI Treatment in Pediatric CML

May 10th 2018

Discontinuation of tyrosine kinase inhibitor treatment may be a possibility for children with chronic myeloid leukemia and, because they could be on-treatment for decades, treatment-free remission is even more important for pediatric patients than for adults.

Dr. Wistinghausen Discusses the Treatment of Pediatric NHL

May 9th 2018

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses the treatment of pediatric patients with non-Hodgkin lymphoma.

Eltrombopag Improves Platelet Count in Pediatric HIV

May 8th 2018

Eltrombopag (Promacta) boosted the platelet count in a 13-year-old boy with HIV-associated thrombocytopenia, according to case study results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.

Dr. Engel on the Use of Eltrombopag in HIV-Related Thrombocytopenia

May 5th 2018

Elissa Engel, MD, pediatric resident, University of South Florida, discusses the successful use of eltrombopag (Promacta) in a pediatric patient with HIV-related thrombocytopenia.

Tazemetostat Shows Antitumor Activity in INI1-Negative Pediatric Tumors

May 4th 2018

Tazemetostat demonstrated promising antitumor activity in pediatric patients with INI1-negative solid tumors.

Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors

May 4th 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of Pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children with INI1-negative tumors.

Dr. Bailey Discusses Key Molecular Pathways in Bone Sarcoma

May 3rd 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses key molecular pathways in pediatric bone sarcoma.

Dr. Crompton Discusses Liquid Biopsies in Pediatric Sarcoma

May 3rd 2018

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the utilization of liquid biopsies in pediatric patients with sarcoma.

AYA Patients With Cancer Want to Know More About Prognosis

May 1st 2018

Adolescent and young adult patients with cancer placed a high importance on prognostic information, and obtaining that knowledge was associated with improved well-being.

FDA Halts Enrollment on Tazemetostat Trials

April 24th 2018

The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.